Eli Lilly and Company is seeking a creative, motivated scientist to join our
Global PK/PD and Pharmacometrics organization.
This scientist will represent Global PK/PD and Pharmacometrics and provide
scientific and technical leadership in the drug discovery, development and
commercialization
Dear all,
I am writing to you as we are currently discussing the implementation of the
MCP-MOD approach for dose finding based on Phase 2B results and would like to
hear your opinion on this approach. It would be good to get feedback from both
statisticians and classical modelers.
I have
Dear Nele, here are some thoughts:
The idea with the MCPmod is twofold,
a) provide a procedure for testing for a treatment effect and in that test
incorporate all doses studies and still maintain control of type I error.
b) If significance in a) continue with framework for estimating the dose
